Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Myomo ( (MYO) ) has issued an announcement.
On April 14, 2026, Myomo appointed William “Will” Febbo to its Board of Directors as a Class II director, expanding the board to six members and positioning him to serve until the 2028 annual meeting of stockholders. Febbo, an experienced healthcare and capital markets executive who currently leads Performance Health Systems and formerly scaled OptimizeRx from a niche product provider into a larger AI-driven platform, is expected to bolster Myomo’s direct-to-patient strategy and enhance its visibility with investors.
In connection with his appointment, Febbo received a grant of 45,000 restricted stock units vesting after one year and will be compensated with an annual cash retainer plus additional RSUs vesting quarterly, aligning his interests with shareholders. Management highlighted that his background in growing healthcare technology businesses and executing capital markets initiatives is intended to support Myomo’s commercial expansion and reinforce its positioning as a potential market leader in advanced upper extremity orthotics.
The most recent analyst rating on (MYO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Myomo stock, see the MYO Stock Forecast page.
Spark’s Take on MYO Stock
According to Spark, TipRanks’ AI Analyst, MYO is a Neutral.
The score is pressured primarily by weak financial performance (ongoing losses, higher cash burn, and reduced equity cushion) and bearish technicals (price below key moving averages with negative MACD). Valuation provides limited offset because the negative P/E reflects unprofitable operations and there is no dividend yield support.
To see Spark’s full report on MYO stock, click here.
More about Myomo
Myomo, Inc. is a wearable medical robotics company that develops and markets the MyoPro line of powered upper-limb orthoses for patients with neurological disorders and upper-limb paralysis. Its EMG-sensing devices are currently the only marketed products in the U.S. that can non-invasively restore arm and hand function to support daily activities and greater independence, with operations based in Burlington, Massachusetts and sales across the U.S. and internationally.
Average Trading Volume: 409,832
Technical Sentiment Signal: Sell
Current Market Cap: $30.81M
For a thorough assessment of MYO stock, go to TipRanks’ Stock Analysis page.